Free public records show PT. Prodia Stem Cell Indonesia in 3 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by PT. Prodia Stem Cell Indonesia or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
10 active studies led by PT. Prodia Stem Cell Indonesia, of 16 in all
Source: ClinicalTrials.gov, Studies with PT. Prodia Stem Cell Indonesia (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies PT. Prodia Stem Cell Indonesia leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with PT. Prodia Stem Cell Indonesia or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show PT. Prodia Stem Cell Indonesia: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets PT. Prodia Stem Cell Indonesia is in.
Stories on the topics PT. Prodia Stem Cell Indonesia works in.
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Doctors' groups such as ACOG support public cord blood donation, but say routine private banking is not…
Read
Every vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
ReadSearch all reports for PT. Prodia Stem Cell Indonesia All companies